Cargando…

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy

Poly(ADP-ribose)polymerase-1 (PARP1) is a DNA repair enzyme highly expressed in the nuclei of mammalian cells, with a structure and function that have attracted interest since its discovery. PARP inhibitors, moreover, can be used to induce synthetic lethality in cells where the homologous recombinat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jannetti, Stephen A., Zeglis, Brian M., Zalutsky, Michael R., Reiner, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062869/ https://www.ncbi.nlm.nih.gov/pubmed/32194409 http://dx.doi.org/10.3389/fphar.2020.00170

Ejemplares similares

Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
por: Dong, Ruihong, et al.
Publicado: (2023)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
por: Inderjeeth, Andrisha-Jade, et al.
Publicado: (2022)

Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
por: Harrision, Daniel, et al.
Publicado: (2020)

High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy
por: Perez-Lopez, Raquel, et al.
Publicado: (2017)

The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors
por: De Soto, Joseph A., et al.
Publicado: (2006)

Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
por: Xu, Qin, et al.
Publicado: (2021)

Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors
por: Faraoni, Isabella, et al.
Publicado: (2018)

Cost-Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Cancer Treatment: A Systematic Review
por: Chan, Vivien Kin Yi, et al.
Publicado: (2022)

Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
por: Boussios, Stergios, et al.
Publicado: (2020)

Associations with response to Poly(ADP-ribose) Polymerase (PARP) inhibitors in patients with metastatic breast cancer
por: Desnoyers, A., et al.
Publicado: (2022)

Myelodysplastic Syndrome/Acute Myeloid Leukemia Following the Use of Poly-ADP Ribose Polymerase (PARP) Inhibitors: A Real-World Analysis of Postmarketing Surveillance Data
por: Zhao, Quanfeng, et al.
Publicado: (2022)

Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes
por: Agarwal, Ashok, et al.
Publicado: (2009)

Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma
por: Vormoor, Britta, et al.
Publicado: (2014)

Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review
por: Sargazi, Saman, et al.
Publicado: (2021)

PARP2 Is the Predominant Poly(ADP-Ribose) Polymerase in Arabidopsis DNA Damage and Immune Responses
por: Song, Junqi, et al.
Publicado: (2015)

Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
por: Zhang, Zhimin, et al.
Publicado: (2020)

Decreasing Poly(ADP-Ribose) Polymerase Activity Restores ΔF508 CFTR Trafficking
por: Anjos, Suzana M., et al.
Publicado: (2012)

Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy
por: Singh, Bijay, et al.
Publicado: (2020)

Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer’s Disease
por: Salech, Felipe, et al.
Publicado: (2020)

Poly(ADP-Ribose) Polymerase 1 (PARP-1) Regulates Ribosomal Biogenesis in Drosophila Nucleoli
por: Boamah, Ernest K., et al.
Publicado: (2012)

Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305
por: Zheng, Jingcao, et al.
Publicado: (2023)

BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents
por: Darabi, Sourat, et al.
Publicado: (2022)

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review
por: Boussios, Stergios, et al.
Publicado: (2019)

Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series
por: Oliveira, Jennifer L., et al.
Publicado: (2022)

Loss of amplified genes by poly(ADP-ribose) polymerase inhibitors.
por: Nagao, M, et al.
Publicado: (1991)

Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
por: Markman, Maurie
Publicado: (2018)

Poly(ADP-ribose) polymerase (PARP-1) is not involved in DNA double-strand break recovery
por: Noël, Georges, et al.
Publicado: (2003)

Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity
por: Fernández-Marcelo, Tamara, et al.
Publicado: (2014)

Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
por: Matanes, Emad, et al.
Publicado: (2021)

RNA regulation by Poly(ADP-ribose) polymerases
por: Bock, Florian J., et al.
Publicado: (2015)

Mitotic functions of poly(ADP-ribose) polymerases
por: Slade, Dea
Publicado: (2019)

The Antiviral Activities of Poly-ADP-Ribose Polymerases
por: Malgras, Mathilde, et al.
Publicado: (2021)

Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
por: Ström, Cecilia E., et al.
Publicado: (2011)

Targeting poly(ADP-ribose) polymerase activity for cancer therapy
por: Mégnin-Chanet, Frédérique, et al.
Publicado: (2010)

Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
por: Miyasaka, Aki, et al.
Publicado: (2014)

Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
por: Cerrato, Aniello, et al.
Publicado: (2016)

RAD54B mutations enhance the sensitivity of ovarian cancer cells to poly(ADP-ribose) polymerase (PARP) inhibitors
por: Liu, Peng, et al.
Publicado: (2022)

Transient HSP90 inhibition enhances the sensitivity of mantle cell lymphoma to poly (ADP-ribose) polymerase (PARP) inhibitors
por: Shi, Chaowen, et al.
Publicado: (2023)

Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy
por: Ström, Cecilia E., et al.
Publicado: (2012)

The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis
por: Yang, Yingzhu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ombptj1u4l5u4gvto50koc6e7k